메뉴 건너뛰기




Volumn 7, Issue 1, 2006, Pages 81-88

Vivitrex Alkermes/Cephalon

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; DISULFIRAM; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MORPHINE; MU OPIATE RECEPTOR; NALTREXOL; NALTREXONE; NEW DRUG; PLACEBO; POLYGLACTIN;

EID: 30944468723     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (4)

References (42)
  • 1
    • 30944465020 scopus 로고    scopus 로고
    • Alkermes releases abstract regarding clinical data for Medisorb naltrexone - Data from first clinical trial of injectable sustained release formulation of alcoholism drug to be presented at December 2000 scientific meeting
    • 390669 Alkermes Inc PRESS RELEASE November 21
    • 390669 Alkermes releases abstract regarding clinical data for Medisorb naltrexone - data from first clinical trial of injectable sustained release formulation of alcoholism drug to be presented at December 2000 scientific meeting. Alkermes Inc PRESS RELEASE 2000 November 21
    • (2000)
  • 2
    • 30944437062 scopus 로고    scopus 로고
    • Alkermes presents phase I results of Medisorb (naltrexone)
    • 393208 Alkermes Inc PRESS RELEASE December 11
    • 393208 Alkermes presents phase I results of Medisorb (naltrexone). Alkermes Inc PRESS RELEASE 2000 December 11
    • (2000)
  • 3
    • 30944438487 scopus 로고    scopus 로고
    • Alkermes reports positive results of phase II clinical trial of Vivitrex for alcohol dependency at Annual Meeting of the American College of Neuropsychopharmacology
    • 432929 Alkermes Inc PRESS RELEASE December 10
    • 432929 Alkermes reports positive results of phase II clinical trial of Vivitrex for alcohol dependency at Annual Meeting of the American College of Neuropsychopharmacology. Alkermes Inc PRESS RELEASE 2001 December 10
    • (2001)
  • 4
    • 4243953360 scopus 로고    scopus 로고
    • Product pipeline
    • 435928 Alkermes Inc COMPANY WORLD WIDE WEB SITE January 15
    • 435928 Product pipeline. Alkermes Inc COMPANY WORLD WIDE WEB SITE 2002 January 15
    • (2002)
  • 5
    • 0031715484 scopus 로고    scopus 로고
    • Sustained-release naltrexone for alcoholism treatment: A preliminary study
    • 441894
    • 441894 Sustained-release naltrexone for alcoholism treatment: A preliminary study. Kranzler HR, Modesto-Lowe V, Neuwayser ES ALCOHOL CLIN EXP RES 1998 22 5 1074-1079
    • (1998) Alcohol Clin Exp Res , vol.22 , Issue.5 , pp. 1074-1079
    • Kranzler, H.R.1    Modesto-Lowe, V.2    Neuwayser, E.S.3
  • 6
    • 30944445015 scopus 로고    scopus 로고
    • Alkermes begins phase III trial of Vivitrex
    • 445176 Alkermes Inc PRESS RELEASE April 01
    • 445176 Alkermes begins phase III trial of Vivitrex. Alkermes Inc PRESS RELEASE 2002 April 01
    • (2002)
  • 7
    • 30944459476 scopus 로고    scopus 로고
    • 455296 DrugAbuse, Sciences Inc. June 09-12
    • 455296 DrugAbuse, Sciences Inc. INT BIOTECHNOL CONV & EXHIB 2002 Suppl June 09-12
    • (2002) Int Biotechnol Conv & Exhib , Issue.SUPPL.
  • 8
    • 30944451174 scopus 로고    scopus 로고
    • Phase III study shows DrugAbuse Sciences naltrexone depot beneficial in treating alcoholism
    • 475512 DrugAbuse Sciences Inc PRESS RELEASE January 06
    • 475512 Phase III study shows DrugAbuse Sciences naltrexone depot beneficial in treating alcoholism. DrugAbuse Sciences Inc PRESS RELEASE 2003 January 06
    • (2003)
  • 9
    • 30944462974 scopus 로고    scopus 로고
    • Alkermes's Vivitrex reduces heavy drinking days by 50%
    • 494451 Alkermes Inc PRESS RELEASE June 23
    • 494451 Alkermes's Vivitrex reduces heavy drinking days by 50%. Alkermes Inc PRESS RELEASE 2003 June 23
    • (2003)
  • 10
    • 30944436857 scopus 로고    scopus 로고
    • Alkermes completes enrollment in long-term safety study of Vivitrex, naltrexone, long-acting injection for the treatment of alcohol depandence
    • 534413 Alkermes Inc PRESS RELEASE April 22
    • 534413 Alkermes completes enrollment in long-term safety study of Vivitrex, naltrexone, long-acting injection for the treatment of alcohol depandence. Alkermes Inc PRESS RELEASE 2004 April 22
    • (2004)
  • 11
    • 30944447308 scopus 로고    scopus 로고
    • Alkermes announces submission of now drug application for Vivitrex for treatment of alcohol dependence
    • 592847 Alkermes Inc PRESS RELEASE April 01
    • 592847 Alkermes announces submission of now drug application for Vivitrex for treatment of alcohol dependence. Alkermes Inc PRESS RELEASE 2005 April 01
    • (2005)
  • 13
    • 30944433611 scopus 로고    scopus 로고
    • Alkermes's Vivitrex gives long-term benefit to alcoholics
    • 603348 Alkermes Inc PRESS RELEASE May 23
    • 603348 Alkermes's Vivitrex gives long-term benefit to alcoholics. Alkermes Inc PRESS RELEASE 2005 May 23
    • (2005)
  • 14
    • 30944448446 scopus 로고    scopus 로고
    • Cephalon and Alkermes announce agreement for the commercialization of Vivitrex for the treatment of alcohol dependence
    • 609280 Cephalon Inc, Alkermes Inc PRESS RELEASE June 24
    • 609280 Cephalon and Alkermes announce agreement for the commercialization of Vivitrex for the treatment of alcohol dependence. Cephalon Inc, Alkermes Inc PRESS RELEASE 2005 June 24
    • (2005)
  • 15
    • 30944453005 scopus 로고    scopus 로고
    • Cephalon - Announces agreement with ALKS to market Vivitrex for alcohol dependence
    • 609507 CIBC WORLD MARKETS CORP June 24
    • 609507 Cephalon - announces agreement with ALKS to market Vivitrex for alcohol dependence. Geller M, Holley B, Kassum T CIBC WORLD MARKETS CORP 2005 June 24 1-11
    • (2005) , pp. 1-11
    • Geller, M.1    Holley, B.2    Kassum, T.3
  • 16
    • 4544222029 scopus 로고    scopus 로고
    • A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence
    • 616443
    • 616443 A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Johnson BA, Ait-Daoud N, Aubin HJ, Van Den Brink W, Guzzetta R, Loewy J, Silverman B, Ehrich E ALCOHOL CLIN EXP RES 2004 28 9 1356-1361
    • (2004) Alcohol Clin Exp Res , vol.28 , Issue.9 , pp. 1356-1361
    • Johnson, B.A.1    Ait-Daoud, N.2    Aubin, H.J.3    Van Den Brink, W.4    Guzzetta, R.5    Loewy, J.6    Silverman, B.7    Ehrich, E.8
  • 17
    • 0242725574 scopus 로고    scopus 로고
    • Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats
    • 616446
    • 616446 Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Bartus RT, Emerich DF, Hotz J, Blaustein M, Dean RL, Perdomo B, Basile AS NEUROPSYCHOPHARMACOLOGY 2003 28 11 1973-1982
    • (2003) Neuropsychopharmacology , vol.28 , Issue.11 , pp. 1973-1982
    • Bartus, R.T.1    Emerich, D.F.2    Hotz, J.3    Blaustein, M.4    Dean, R.L.5    Perdomo, B.6    Basile, A.S.7
  • 18
    • 30944468352 scopus 로고    scopus 로고
    • FDA extends PDUFA date for Vivitrex to December 30, 2005; Cephalon and Alkermes continue to anticipate Vivitrex launch in first half of 2006
    • 624146 Celphalon Inc, Alkermes Inc PRESS RELEASE September 20
    • 624146 FDA extends PDUFA date for Vivitrex to December 30, 2005; Cephalon and Alkermes continue to anticipate Vivitrex launch in first half of 2006. Celphalon Inc, Alkermes Inc PRESS RELEASE 2005 September 20
    • (2005)
  • 19
    • 2442658861 scopus 로고    scopus 로고
    • Opioids and alcoholism
    • 631895
    • 631895 Opioids and alcoholism. Oswald LM, Wand GS PHYSIOL BEHAV 2004 81 2 339-358
    • (2004) Physiol Behav , vol.81 , Issue.2 , pp. 339-358
    • Oswald, L.M.1    Wand, G.S.2
  • 20
    • 26844446453 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: An open-label trial
    • 631898
    • 631898 Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: An open-label trial. Galloway GP, Koch M, Cello R, Smith DE BMC PSYCHIATRY 2005 5 1 18
    • (2005) BMC Psychiatry , vol.5 , Issue.1 , pp. 18
    • Galloway, G.P.1    Koch, M.2    Cello, R.3    Smith, D.E.4
  • 21
    • 27744484789 scopus 로고    scopus 로고
    • Acamprosate for the treatment of alcohol dependence
    • 631992
    • 631992 Acamprosate for the treatment of alcohol dependence. Boothby LA, Doering PL CLIN THER 2005 27 6 695-714
    • (2005) Clin Ther , vol.27 , Issue.6 , pp. 695-714
    • Boothby, L.A.1    Doering, P.L.2
  • 22
    • 26944473179 scopus 로고    scopus 로고
    • Histological changes over time around the site of sustained release naltrexone-poly(DL-lactide) implants in humans
    • 631995
    • 631995 Histological changes over time around the site of sustained release naltrexone-poly(DL-lactide) implants in humans. Hulse GK, Stalenberg V, McCallum D, Smit W, O'Neil G, Morris N, Tait RJ J CONTROL RELEASE 2005 108 1 43-55
    • (2005) J Control Release , vol.108 , Issue.1 , pp. 43-55
    • Hulse, G.K.1    Stalenberg, V.2    McCallum, D.3    Smit, W.4    O'Neil, G.5    Morris, N.6    Tait, R.J.7
  • 23
    • 30944450824 scopus 로고    scopus 로고
    • Alkermes reports second quarter fiscal 2006 financial results; company reports profitable quarter; financial expectations for fiscal 2006 Improve
    • 632485 Alkermes Inc PRESS RELEASE November 03
    • 632485 Alkermes reports second quarter fiscal 2006 financial results; company reports profitable quarter; financial expectations for fiscal 2006 Improve. Alkermes Inc PRESS RELEASE 2005 November 03
    • (2005)
  • 25
    • 0035948997 scopus 로고    scopus 로고
    • Naltrexone implants for opiate addiction: New life for a middle-aged drug
    • 636732 162
    • 636732 Naltrexone implants for opiate addiction: New life for a middle-aged drug. Brew C PHARW J 2001 267 7 162 260
    • (2001) Pharw J , vol.267 , Issue.7 , pp. 260
    • Brew, C.1
  • 26
    • 30944445620 scopus 로고    scopus 로고
    • DrugAbuse Sciences Product Portfolio
    • 636738 DrugAbuse Sciences Inc COMPANY COMMUNICATION November 17
    • 636738 DrugAbuse Sciences Product Portfolio. DrugAbuse Sciences Inc COMPANY COMMUNICATION 2005 November 17
    • (2005)
  • 27
    • 0033561459 scopus 로고    scopus 로고
    • Drug addiction: Bad habits add up
    • 636843
    • 636843 Drug addiction: Bad habits add up. Robbins TW, Everitt BJ NATURE 1999 388 6728 567-570
    • (1999) Nature , vol.388 , Issue.6728 , pp. 567-570
    • Robbins, T.W.1    Everitt, B.J.2
  • 28
    • 0030763094 scopus 로고    scopus 로고
    • Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States: Results of the National Longitudinal Alcohol Epidemiologic Survey
    • 637673
    • 637673 Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States: Results of the National Longitudinal Alcohol Epidemiologic Survey. Grant BF J STUD ALCOHOL 1997 58 5 464-473
    • (1997) J Stud Alcohol , vol.58 , Issue.5 , pp. 464-473
    • Grant, B.F.1
  • 29
    • 0027938307 scopus 로고
    • Alcohol consumption, alcohol abuse and alcohol dependence. The United States as an example
    • 637682
    • 637682 Alcohol consumption, alcohol abuse and alcohol dependence. The United States as an example. Grant BF ADDICTION 1994 89 11 1357-1365
    • (1994) Addiction , vol.89 , Issue.11 , pp. 1357-1365
    • Grant, B.F.1
  • 30
    • 0037810374 scopus 로고    scopus 로고
    • Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: A pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels
    • 637696
    • 637696 Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: A pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Foster J, Brewer C, Steele T ADDICT BIOL 2003 8 2 211-217
    • (2003) Addict Biol , vol.8 , Issue.2 , pp. 211-217
    • Foster, J.1    Brewer, C.2    Steele, T.3
  • 31
    • 0032424267 scopus 로고    scopus 로고
    • Effects of naltrexone administered repeatedly across 30 or 60 days on ethanol consumption using a limited access procedure in the rat
    • 637699
    • 637699 Effects of naltrexone administered repeatedly across 30 or 60 days on ethanol consumption using a limited access procedure in the rat. Stromberg MF, Volpicelli JR, O'Brien CP ALCOHOL CLIN EXP RES 1998 22 9 2186-2191
    • (1998) Alcohol Clin Exp Res , vol.22 , Issue.9 , pp. 2186-2191
    • Stromberg, M.F.1    Volpicelli, J.R.2    O'Brien, C.P.3
  • 36
    • 0030824843 scopus 로고    scopus 로고
    • Naltrexone biotransformation and incidence of subjective side effects: A preliminary study
    • 638460
    • 638460 Naltrexone biotransformation and incidence of subjective side effects: A preliminary study. King AC, Volpicelli JR, Gunduz M, O'Brien CP, Kreek MJ ALCOHOL CLIN EXP RES 1997 21 5 906-909
    • (1997) Alcohol Clin Exp Res , vol.21 , Issue.5 , pp. 906-909
    • King, A.C.1    Volpicelli, J.R.2    Gunduz, M.3    O'Brien, C.P.4    Kreek, M.J.5
  • 37
    • 19444361830 scopus 로고    scopus 로고
    • In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice
    • 638466
    • 638466 In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. Raehal KM, Lowery JJ, Bhamidipati CM, Paolino RM, Blair JR, Wang D, Sadee W, Bilsky EJ J PHARMACOL EXP THER 2005 313 3 1150-1162
    • (2005) J Pharmacol Exp Ther , vol.313 , Issue.3 , pp. 1150-1162
    • Raehal, K.M.1    Lowery, J.J.2    Bhamidipati, C.M.3    Paolino, R.M.4    Blair, J.R.5    Wang, D.6    Sadee, W.7    Bilsky, E.J.8
  • 38
    • 0029072710 scopus 로고
    • Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: Relationship to receptor selectivity
    • 638481
    • 638481 Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: Relationship to receptor selectivity. Yobum BC, Shah S, Chan K, Duttaroy A, Divis T PHARMACOL BIOCHEM BEHAV 1995 51 2-3 535-539
    • (1995) Pharmacol Biochem Behav , vol.51 , Issue.2-3 , pp. 535-539
    • Yobum, B.C.1    Shah, S.2    Chan, K.3    Duttaroy, A.4    Divis, T.5
  • 40
    • 0033553203 scopus 로고    scopus 로고
    • Pharmacological treatment of alcohol dependence. A review of the evidence
    • 638487
    • 638487 Pharmacological treatment of alcohol dependence. A review of the evidence. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT J AM MED ASSOC 1999 281 14 1318-1325
    • (1999) J Am Med Assoc , vol.281 , Issue.14 , pp. 1318-1325
    • Garbutt, J.C.1    West, S.L.2    Carey, T.S.3    Lohr, K.N.4    Crews, F.T.5
  • 41
    • 30944462204 scopus 로고    scopus 로고
    • Product portfolio: Naltrexone, depot
    • 638704 DrugAbuse Sciences Inc COMPANY WORLD WIDE WEB SITE December
    • 638704 Product portfolio: Naltrexone, depot. DrugAbuse Sciences Inc COMPANY WORLD WIDE WEB SITE December 2005
    • (2005)
  • 42
    • 30944462205 scopus 로고
    • The abuse of alcohol and drugs
    • 638730 Third Edition. Gelder M, Mayou R, Cowen P (Eds). Oxford University Press, Oxford, UK
    • 638730 The abuse of alcohol and drugs. In: The Oxford Textbook of Psychiatry, Third Edition. Gelder M, Mayou R, Cowen P (Eds). Oxford University Press, Oxford, UK 1995 14 456-481
    • (1995) The Oxford Textbook of Psychiatry , vol.14 , pp. 456-481


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.